BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced that President and Chief Executive Officer Kerrie Brady has been named to the PharmaVoice 100, an annual list of the most inspiring people in life sciences. A prestigious honor in the life sciences industry for nearly 20 years, the PharmaVoice 100 recognizes leaders who have been instrumental in propelling the industry forward and in uplifting employees and patients.
After joining OcuTerra in 2020, Ms. Brady repositioned the company to enable earlier, non-invasive treatment for diabetic retinopathy through the development of OTT166, a novel small molecule RGD integrin inhibitor designed to be delivered via eye drop. Since joining the company, Ms. Brady has led numerous company milestones including:
- Securing $35 million in Series B fundraising to support the continued clinical development of OTT166.
- Initiating and reaching full enrollment for the company’s Phase 2 DR:EAM clinical trial evaluating OTT166 in diabetic retinopathy.
- Recruiting several key members of the executive team, including Chief Medical Officer David Tanzer, MD, and Chief Financial Officer Bill Steinkrauss, as well as Chairman of the Board of Directors Brent Saunders.
“Throughout my career, I’ve been motivated by the potential to translate groundbreaking science into life-changing therapeutics for patients not adequately served by currently available treatments,” said Ms. Brady. “Working alongside the OcuTerra team, we have developed a much-needed non-invasive intervention to enable earlier treatment of diabetic retinopathy, and it is an honor to be recognized by PharmaVoice for the work I love doing.”
To learn more about Ms. Brady’s impact at OcuTerra and the industry at large, read the full feature on PharmaVoice.com.
About OcuTerra Therapeutics
OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the [early] progression of disease. Our initial therapeutic candidate, OTT166, administered as an eye drop containing a novel, potent and selective integrin-inhibitor, is in clinical development as an early, non-invasive intervention for diabetic retinopathy, a chronic, progressive disease that is one of the leading causes of vision loss globally. Our goal is to bring transformative treatments to patients and their clinicians who are currently consigned to watch and wait as disease progresses, ultimately requiring medically intensive and invasive therapy. www.ocuterratx.com
Contacts
MacDougall Advisors
Carolyn Noyes
cnoyes@macdougall.bio
781-235-3060